Phil Berman has been working to develop an AIDS vaccine for nearly 30 years. Now his lab has developed new vaccine candidates that he said are promising enough to consider advancing into clinical trials within the next two years.
Male HIV patients in rural South Africa reach the low immunity levels required to become eligible for antiretroviral treatment in less than half the time it takes for immunity levels to drop to similar levels in women, according to new research from the University of Southampton.
the human immunodeficiency virus (HIV) is a bit like a hermetically sealed tin can no one has yet been able to break open, the good news is that researchers have identified a way to use a “can opener” to force the virus to open up and to expose its vulnerable parts, allowing the immune system cells to then kill the infected cells.
Patients with acquired immunodeficiency syndrome (AIDS) have a four-fold increase in their risk of developing intermediate-stage age-related macular degeneration (AMD) compared to people of the same age who are not infected with HIV, according to results from the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) presented today at the 2015 ARVO Annual Meeting in Denver, CO.
Risk of developing age-related macular degeneration higher in patients with AIDS Denver, Colo. – Patients with acquired immunodeficiency syndrome (AIDS) have a four-fold increase in their risk of developing intermediate-stage age-related macular degeneration (AMD) compared to people of the same age who are not infected with HIV, according to results from the Longitudinal Study of the Ocular Complications of AIDS (LSOCA). The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Denver, Colo.
Patients infected with human immunodeficiency virus (HIV) can, in rare cases, experience bleeding on the brain that causes a type of stroke called intracerebral hemorrhage.
Researchers reveal how a Rab protein that controls intracellular trafficking supports HIV-1 assembly by promoting high levels of an important membrane lipid.
Young HIV positive women are more likely to practice safer sex if they have an equitable perception of gender roles, according to new research involving the University of Southampton.
Scientists report that a new study of HIV-infected men in Uganda has identified a temporary, but potentially troublesome unintended consequence of the procedure: a possible increased risk of infecting female sexual partners while circumcision wounds heal.
The peak time for seeking information on topics related to HIV, such as prevention and testing, is at the beginning of the week, while risky sexual behaviors tend to increase on the weekends, according to a new analysis by researchers at the Johns Hopkins Bloomberg School of Public Health and the Monday Campaigns.
Discussing your sexual history with a doctor, or anyone for that matter, can be an uncomfortable experience. But for many transgender people, the conversation never takes place because they aren’t seeking health care.
Bars and street corners are ideal venues for broad dissemination of HIV prevention information among drug-using male sex workers and other at-risk populations, according to researchers from The University of Texas Health Science Center at Houston (UTHealth).
University at Buffalo researchers have discovered a way to easily and effectively fasten proteins to nanoparticles – essentially an arranged marriage – by simply mixing them together. The biotechnology, described April 20 online in the journal Nature Chemistry, is in its infancy. But it already has shown promise for developing an HIV vaccine and as a way to target cancer cells.
Michael Saag, M.D., spreads message from first book to TEDxBirmingham attendees; says three lessons can help enact change.
Dartmouth study finds some portions of the female reproductive tract are more likely to be infected by HIV, particularly the ectocervix compared to the endometrium.
Research suggests that HIV induces age-associated changes to the DNA, which in turn lead to earlier onset of age-related illnesses such as some cancers, renal and kidney disease, frailty, osteoporosis and neurocognitive diseases by more than 14 years.
The intervention was found to be feasible and acceptable. Eight months post-baseline, intervention participants tended to be more likely to evidence “good” (that is, 7 day a week) adherence assessed via hair sample analysis (60% among intervention arm participants vs. 26.7% among controls), and also had lower HIV viral load levels based on the medical record than controls, at a statistically significant level (a difference of 0.88 log10 viral load), both large effect sizes. Thus the intervention components were highly promising, and merit further study with this vulnerable population.
HIV (human immunodeficiency virus)-positive kidney transplant patients experienced superior outcomes when compared to kidney transplant patients with Hepatitis C and those infected with both HIV and Hepatitis C, according to a study led by researchers at the Perelman School of Medicine at the University of Pennsylvania and published online in Kidney International.
Most children with HIV who have low levels of a key immune cell eventually recover levels of this cell after they begin treatment.
• Compared with uninfected (HIV-/HCV-) kidney transplant recipients, mono-infected HIV+ (HIV+/HCV-) recipients had similar 5-year and 10-year kidney survival rates, while HIV+ recipients co-infected with HCV (HIV+/HCV+) had worse kidney survival rates. • Patient survival among mono-infected HIV+ recipients was similar to uninfected recipients but was significantly lower for co-infected recipients.
Kidney recipients infected only with HIV do as well as uninfected recipients, but HIV-infected recipients co-infected with hepatitis C virus have poorer outcomes.
Case Western Reserve researchers are part of an international team that has discovered that Valacyclovir reduces HIV-1 levels — even when patients do not have herpes. Results were published online in Clinical Infectious Disease.
Since HIV emerged in the ‘80s, drug “cocktails” transformed the deadly disease into a manageable one. But the virus is adept at developing resistance to drugs, and treatment regimens require tweaking that can be costly. Now scientists at the 249th National Meeting & Exposition of the American Chemical Society are announcing new progress toward affordable drugs that could potentially thwart the virus’s ability to resist them.
Salk scientists re-engineered the bacterial defense system CRISPR to recognize HIV inside human cells and destroy the virus, offering a potential new therapy.
Two of the four known groups of human AIDS viruses (HIV-1 groups O and P) have originated in western lowland gorillas, according to an international team of scientists.
In a remarkable new advance against the virus that causes AIDS, scientists from The Scripps Research Institute have announced the creation of a novel drug candidate so potent and universally effective, it might work as part of an unconventional vaccine.
Reporting in a new study published online this week in The Lancet Infectious Diseases, researchers under the Botswana-UPenn Partnership at the University of Pennsylvania, including Shruthi Ravimohan, PhD, a research associate in the division of Infectious Diseases at Penn’s Perelman School of Medicine, and Gregory P. Bisson, MD, MSCE, an assistant professor in the division of Infectious Diseases, have identified immune biomarkers in HIV/TB patients before they begin ART that could help distinguish who goes on to develop IRIS or die after treatment.
Columbia Engineering Professor Samuel Sia has developed a low-cost smartphone accessory that can perform a point-of-care test that simultaneously detects three infectious disease markers—HIV and syphilis—from a finger prick of blood in just 15 minutes. The device replicates, for the first time, all mechanical, optical, and electronic functions of a lab-based blood test without requiring any stored energy: all necessary power is drawn from the smartphone. February 4, Science Translational Medicine.
New findings, published today by researchers at the University of California, San Diego School of Medicine, open the door to the development of new therapies to block or decrease cognitive decline due to HIV-associated neurocognitive disorders (HAND), estimated to affect 10 to 50 percent of aging HIV sufferers to some degree.
One of the global regions highly affected by hepatitis C is West Africa. In developed countries, hepatitis C, a blood-borne disease, is transmitted through intravenous (IV) drug use. “In West Africa, we believe that there are many transmission modes and they are not through IV drug use, but through cultural and every day practices,” says Jennifer Layden, MD, PhD principal investigator on a study recently published in the journal Clinical Infectious Diseases.
The antibody response from an HIV vaccine trial in Thailand was made possible by a genetic trait carried over in humans from an ancient ancestry with monkeys and apes, according to a study led by Duke Medicine researchers.
Luring dormant HIV out of hiding and destroying its last cure-defying holdouts has become the holy grail of HIV eradication, but several recent attempts to do so have failed. Now the findings of a Johns Hopkins-led study reveal why that is and offer a strategy that could form a blueprint for a therapeutic vaccine to eradicate lingering virus from the body.
Loyola University Health System has now expanded free HIV testing to patients at the Loyola Center for Health at River Forest. “HIV affects people of all ages, all races and all economic backgrounds; it is not just an urban phenomenon but exists in the suburbs,” says Jerry Goldstein, research coordinator, Loyola University Health System. ”The more people tested, the earlier the detection and the faster treatment is offered to save lives and prevent the spread of infection.”
Social media such as Twitter and Facebook, combined with behavioral psychology, could be a valuable tool in the fight against AIDS by prompting high-risk individuals to be tested.
Secondary infection with the hepatitis C virus does not contribute to the mental impairments seen in many long-term survivors of HIV infection, a new study reveals.
A new retrospective study by epidemiologists at Tufts finds significant geographic disparities in HIV and hepatitis C related mortality in Massachusetts from 2002-2011. The study, published in PLOS ONE, used geospatial techniques to identify hotspots and coldspots in the state.
People with mental illness are more likely to have been tested for HIV than those without mental illness, according to a new study from a team of researchers at Penn Medicine and the U.S. Centers for Disease Control and Prevention (CDC) published online this week in AIDS Patient Care and STDs. The researchers also found that the most seriously ill – those with schizophrenia and bipolar disease – had the highest rate of HIV testing.
To stop the spread of HIV in Africa, researchers at UCLA, using a complex mathematical model, have developed a strategy that focuses on targeting “hot zones,” areas where the risk of HIV infection is much higher than the national average.
Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers funded by the National Institutes of Health (NIH) have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.
Just-published findings in the journal AIDS raise concern about potential long-term harmful impact of “antiretroviral therapy” on in-utero infants whose mothers are HIV-positive, but who are not infected with HIV themselves.
A landmark study published today in the journal Science by an international group of scientists, led by the laboratory of Dr. Jayakrishna Ambati, professor and vice chair of the Department of Ophthalmology & Visual Sciences at the University of Kentucky, reports that HIV/AIDS drugs that have been used for the last 30 years could be repurposed to treat age-related macular degeneration (AMD), as well as other inflammatory disorders, because of a previously undiscovered intrinsic and inflammatory activity those drugs possess.
In the 1980s, when HIV/AIDS was a new, mysterious and inevitably fatal illness, Dr. James Oleske of what is new Rutgers New Jersey Medical School earned renown for caring for children who would inevitably die from AIDS, and for uncovering some of its important secrets. With HIV under much better control, Oleske has now turned his attention to being a champion of palliative care for children who are terribly ill with other fatal conditions.
New research from the Johns Hopkins Bloomberg School of Public Health suggests that HIV-infected adults are at a higher risk for developing heart attacks, kidney failure and cancer. But, contrary to what many had believed, the researchers say these illnesses are occurring at similar ages as adults who are not infected with HIV.
The study’s results suggest three themes: (1) local demand shifts drug routes to tourism areas, (2) drugs shape local economies and (3) drug use facilitates HIV risk behaviors in tourism areas.
Salk scientists identify a promising target for HIV/AIDS treatment
Student, alumni interest in care and prevention are alive and well at Hopkins School of Nursing and beyond.
New clinical research from UC San Francisco shows that 341 HIV-infected men who reported using stimulants such as methamphetamine or cocaine derived life-saving benefits from being on antiretroviral therapy that were comparable to those of HIV-infected men who do not use stimulants.
Mymetics Corporation (OTCQB: MYMX) announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm results obtained in a previous trial. Research is to be funded by the Bill & Melinda Gates Foundation. The study will be led by Dr. Ruth Ruprecht, Scientist & Director of the Texas Biomed AIDS Research Program.
Scientists at The Scripps Research Institute (TSRI) have described how a single family of antibodies that broadly neutralizes different strains of HIV has evolved remarkably diverse structures to attack a vulnerable site on the virus. The findings provide clues for the design of a future HIV vaccine.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right